PBB3 binding in a patient with corticobasal syndrome

Mov Disord. 2018 Aug;33(8):1359-1360. doi: 10.1002/mds.27405. Epub 2018 Jun 22.

Authors

Alexandra Perez-Soriano¹, Michele Matarazzo¹, Nasim Vafai², Elham Shahinfard², Qing Miao³, Makoto Higuchi⁴, Vesna Sossi², A Jon Stoessl¹

Affiliations

¹ Pacific Parkinson's Research Centre & Djavad Mowafaghian Centre for Brain Health, University of British Columbia and Vancouver Coastal Health, Vancouver, British Columbia, Canada.
² Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia, Canada.
³ TRIUMF.
⁴ National Institute of Radiological Sciences and National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.

PMID: 29932465
DOI: 10.1002/mds.27405

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Basal Ganglia / diagnostic imaging
Basal Ganglia / drug effects*
Benzothiazoles / metabolism*
Benzothiazoles / pharmacokinetics
Carbon Radioisotopes / pharmacokinetics
Cerebral Cortex / diagnostic imaging
Cerebral Cortex / drug effects*
Humans
Magnetic Resonance Imaging
Male
Neurodegenerative Diseases / metabolism*
Neurodegenerative Diseases / pathology*

Substances

Benzothiazoles
Carbon Radioisotopes
PBB3 compound